LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Sold by AWM Investment Company Inc.

AWM Investment Company Inc. lowered its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 9.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 150,000 shares of the medical instruments supplier’s stock after selling 15,000 shares during the period. LeMaitre Vascular accounts for approximately 1.7% of AWM Investment Company Inc.’s portfolio, making the stock its 26th largest position. AWM Investment Company Inc. owned 0.67% of LeMaitre Vascular worth $13,821,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of LMAT. Smartleaf Asset Management LLC lifted its holdings in LeMaitre Vascular by 234.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier’s stock worth $39,000 after buying an additional 293 shares during the last quarter. CBIZ Investment Advisory Services LLC lifted its stake in LeMaitre Vascular by 38.5% during the fourth quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier’s stock worth $39,000 after purchasing an additional 117 shares during the last quarter. KBC Group NV lifted its stake in LeMaitre Vascular by 58.4% during the fourth quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier’s stock worth $102,000 after purchasing an additional 410 shares during the last quarter. Huntington National Bank boosted its holdings in LeMaitre Vascular by 64.9% in the fourth quarter. Huntington National Bank now owns 1,156 shares of the medical instruments supplier’s stock valued at $107,000 after purchasing an additional 455 shares in the last quarter. Finally, Empowered Funds LLC purchased a new position in LeMaitre Vascular in the fourth quarter valued at approximately $150,000. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Stock Down 1.4%

Shares of LMAT stock opened at $84.75 on Wednesday. The stock’s 50-day moving average price is $84.27 and its 200 day moving average price is $92.91. The stock has a market capitalization of $1.91 billion, a PE ratio of 46.31, a price-to-earnings-growth ratio of 2.22 and a beta of 0.86. LeMaitre Vascular, Inc. has a 52-week low of $71.42 and a 52-week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.02). LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The company had revenue of $59.87 million during the quarter, compared to analyst estimates of $57.61 million. During the same period in the previous year, the firm posted $0.44 EPS. The company’s revenue for the quarter was up 12.0% on a year-over-year basis. Analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, May 29th. Stockholders of record on Thursday, May 15th will be paid a dividend of $0.20 per share. The ex-dividend date is Thursday, May 15th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.94%. LeMaitre Vascular’s dividend payout ratio (DPR) is 40.40%.

Insider Buying and Selling

In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,009 shares of the business’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total transaction of $164,979.08. Following the sale, the insider now directly owns 5,564 shares in the company, valued at approximately $456,915.68. The trade was a 26.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO George W. Lemaitre sold 4,399 shares of the company’s stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $85.10, for a total transaction of $374,354.90. Following the transaction, the chief executive officer now directly owns 1,827,003 shares in the company, valued at approximately $155,477,955.30. This trade represents a 0.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 102,009 shares of company stock valued at $8,721,836 over the last ninety days. Corporate insiders own 9.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Wells Fargo & Company assumed coverage on shares of LeMaitre Vascular in a research report on Thursday, February 13th. They set an “equal weight” rating and a $95.00 price objective for the company. Lake Street Capital boosted their price target on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the company a “buy” rating in a research report on Friday, February 28th. Barrington Research lowered LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th. Finally, Oppenheimer cut LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. Five investment analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $98.14.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.